Published in Healthcare Mergers, Acquisitions and Ventures Week, February 26th, 2005
The phase I study, which will be conducted at university clinics in Gottingen and Frankfurt/Main in Germany, will evaluate the safety (including maximum tolerated dose and dose-limiting toxicity) and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week